Pfizer, Wyeth Japan Subsidiaries Merge To Become Second-largest Pharma
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Pfizer Japan and Wyeth Japan, both of them fully owned by their U.S. parent firms, announced their merger, effective June 1, becoming Japan's second-largest pharmaceutical manufacturer after Takeda Pharmaceutical Co. and expanding Pfizer Japan's cardio and neural product lineup with Wyeth's vaccines
You may also be interested in...
Pfizer Invests $100 Million To Expand Singapore Nutrition Plant
SINGAPORE - Pfizer has invested $100 million in its Singapore nutrition factory, increasing its production capacity by 50 percent, as the company eyes infant nutrition opportunities in Asia
Pfizer Invests $100 Million To Expand Singapore Nutrition Plant
SINGAPORE - Pfizer has invested $100 million in its Singapore nutrition factory, increasing its production capacity by 50 percent, as the company eyes infant nutrition opportunities in Asia
Japanese Regulators Recommend Wyeth-Pfizer's Torisel And Celgene's Revlimid For Approval
The Second Committee on New Drugs at Japan's Ministry of Health, Labor and Welfare on May 31 recommended Wyeth-Pfizer's Torisel (temsirolimus) and Celgene's Revlimid (lenalidomide) for approval. The approvals came with post-market surveillance requirements and a restricted distribution system in the case of Revlimid